VOLUME 3, ISSUE 2, P175, JUNE 01, 2022
Baris Ata, M.D., M.Sc., Engin Turkgeldi, M.D., M.Sc., Sule Yildiz, M.D., Berk Angun, M.D., Bulent Urman, M.D.
We read the article by Banker et al. (1) with pleasure because their results support our prior observations (2, 3, 4). We had also compared 2 matched cycles of 59 oocyte donors, 1 with follicular estradiol scheduling (FES) and 1 without (2, 3). Both were flexible gonadotropin-releasing hormone antagonist cycles; however, different from the study by Banker et al. (1), we administered 2 mg of estradiol valerate tablets 3 times a day, from cycle day 2 until commencement of gonadotropins on a scheduled day (1, 2).